Physician profile
Sameer Gupta
NPI 1720287436
$11,039.04
in general payments reported to CMS, 2019-2025
46 companies · $2,650 in 2025
The $2,650 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $823 · 2020: $541 · 2021: $1,203 · 2022: $1,780 · 2023: $2,264 · 2024: $1,777 · 2025: $2,650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,669 · Education: $22.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,668.98 |
| Education | $22.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,799.89 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Genzyme Corporation | $1,320.29 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $981.73 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $798.93 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $545.83 | 2020-2025 | Takhzyro, Cuvitru, Hyqvia |
| Csl Behring | $473.97 | 2020-2025 | Hizentra |
| Grifols USA, LLC | $430.17 | 2022-2025 | Xembify, Gamunex-C |
| Pfizer INC. | $415.83 | 2019-2025 | |
| Optinose US, INC. | $384.07 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $348.01 | 2019-2025 | |
| Kaleo, INC. | $283.93 | 2019-2024 | Auvi-Q |
| Boehringer Ingelheim Pharmaceuticals, INC. | $260.05 | 2020-2024 | Spiriva Respimat |
| Horizon Therapeutics Plc | $239.07 | 2021-2023 | Krystexxa |
| Blueprint Medicines Corporation | $198.66 | 2022-2025 | Ayvakit |
| Incyte Corporation | $197.18 | 2022-2023 | Opzelura |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameer Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.